Neurode
Drug free, non-invasive treatment of ADHD.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
* | N/A | $10.0m | Early VC |
| Total Funding | 000k | ||
| USD | 2022 | 2023 |
|---|---|---|
| Revenues | 0000 | 0000 |
| % growth | - | 33 % |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Neurode Labs operates in the cutting-edge field of brain-computer interfaces (BCIs), focusing on enhancing cognitive function and emotional well-being. The company serves a diverse range of clients, including individuals seeking cognitive enhancement, healthcare providers, and research institutions. Neurode Labs operates in the health tech market, leveraging advanced algorithms and optical systems to develop its products. The business model is primarily B2C (business-to-consumer), selling its products directly to end-users through its website and other online platforms. Revenue is generated through the sale of its BCI devices and related software subscriptions. The company's innovative approach aims to provide non-invasive solutions that help users improve their mental health and cognitive abilities.
Keywords: brain-computer interface, cognitive enhancement, emotional well-being, health tech, advanced algorithms, optical systems, B2C, non-invasive solutions, mental health, cognitive abilities.